Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical study to evaluate nirogacestat in combination with SEA-BCMA in patients with relapsed or refractory multiple myeloma

Next Previous
X
Search
Trial Profile

A phase I clinical study to evaluate nirogacestat in combination with SEA-BCMA in patients with relapsed or refractory multiple myeloma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nirogacestat (Primary) ; SEA-BCMA (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Seagen

    • Most Recent Events

    • 04 Nov 2021 According to a SpringWorks Therapeutics media release, this study is expected to initiate in the first quarter of 2022.
    • 14 Jun 2021 New trial record
    • 07 Jun 2021 According to a SpringWorks Therapeutics media release, the company has entered into a clinical trial collaboration agreement with Seagen Inc. to evaluate nirogacestat,, in combination with SEA-BCMA, in patients with relapsed or refractory multiple myeloma. Seagen and SpringWorks will also form a joint development committee to manage the clinical study, which is expected to commence in the second half of 2021. Seagen will sponsor and conduct the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top